Shirley Kuhlmann, Executive Vice President and General Counsel of Collegium Pharmaceutical Inc (COLL, Financial), sold 25,000 shares of the company on June 3, 2024. The transaction was reported in a recent SEC Filing. Following this transaction, the insider now owns 139,409 shares of the company.
Collegium Pharmaceutical Inc is engaged in the development and commercialization of treatments for pain and other conditions. The company's products are designed to improve patient outcomes and address unmet medical needs.
Over the past year, Shirley Kuhlmann has sold a total of 68,584 shares and has not made any purchases of the company's stock. This recent sale is part of a broader trend observed within the company, where there have been 10 insider sells and no insider buys over the past year.
On the day of the sale, shares of Collegium Pharmaceutical Inc were trading at $32.57, giving the company a market cap of $1.037 billion. The price-earnings ratio of the company stands at 13.16, which is lower than the industry median of 23.03 and also below the company's historical median.
According to the GF Value, the intrinsic value of the stock is estimated at $28.08, which suggests that the stock is Modestly Overvalued with a price-to-GF-Value ratio of 1.16.
The GF Value is calculated based on historical trading multiples, a GuruFocus adjustment factor based on past returns and growth, and future business performance estimates provided by Morningstar analysts.
This sale by Shirley Kuhlmann might be of interest to investors tracking insider activities, especially considering the stock's valuation and recent trading price relative to its GF Value.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
